



Noyce, A. J., Bandres-Ciga, S., Kim, J., Helibron, K., Kia, D. A., Hemani, G., ... the 23 and Me Research Team (2019). The Parkinson's Disease Mendelian Randomization Research Portal. *Movement Disorders*, 34(12), 1864 - 1872. <https://doi.org/10.1002/mds.27873>

Publisher's PDF, also known as Version of record

License (if available):
CC BY

Link to published version (if available):
[10.1002/mds.27873](https://doi.org/10.1002/mds.27873)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the final published version of the article (version of record). It first appeared online via Wiley at <https://doi.org/10.1002/mds.27873> . Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/pure/about/ebr-terms>

The Parkinson's Disease Mendelian Randomization Research Portal

Alastair J. Noyce, MRCP, PhD,^{1,2*} Sara Bandres-Ciga, PhD,^{3,4} Jonggeol Kim, BSc,³ Karl Heilbron, PhD,⁵ Demis Kia, BSc,² Gibran Hemani, PhD,⁶ Angli Xue, BSc,^{7,8} Debbie A. Lawlor, PhD,^{6,9} George Davey Smith, MD,^{6,9} Raquel Duran, PhD,^{4,10} Ziv Gan-Or, MD, PhD,^{11,12,13} Cornelis Blauwendraat, PhD,³ J. Raphael Gibbs, PhD,³ 23andMe Research Team⁵, International Parkinson's Disease Genomics Consortium (IPDGC), David A. Hinds, PhD,⁵ Jian Yang, PhD,^{7,8,14} Peter Visscher, PhD,^{7,8} Jack Cuzick, PhD,¹ Huw Morris, FRCP, PhD,² John Hardy, PhD,² Nicholas W. Wood, FRCP, PhD,² Mike A. Nalls, PhD,^{3,15} and Andrew B. Singleton, PhD³

¹Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom

²Department of Clinical and Movement Neurosciences, University College London, Institute of Neurology, London, United Kingdom

³Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA

⁴Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain

⁵23andMe, Inc., Mountain View, California, USA

⁶MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom

⁷Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia

⁸Queensland Brain Institute, The University of Queensland, Brisbane, Queensland, Australia

⁹Population Health Science, Bristol Medical School, University of Bristol, Bristol, United Kingdom

¹⁰Centro de Investigación Biomedica and Departamento de Fisiología, Facultad de Medicina, Universidad de Granada, Granada, Spain

¹¹Department of Neurology & Neurosurgery, McGill University, Montreal, Quebec, Canada

¹²Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada

¹³Department of Human Genetics, McGill University, Montreal, Quebec, Canada

¹⁴Institute for Advanced Research, Wenzhou Medical University, Wenzhou, Zhejiang, China

¹⁵Data Tecnica International, Glen Echo, Maryland, USA

ABSTRACT: Background: Mendelian randomization is a method for exploring observational associations to find evidence of causality.

Objective: To apply Mendelian randomization between risk factors/phenotypic traits (exposures) and PD in a large, unbiased manner, and to create a public resource for research.

Methods: We used two-sample Mendelian randomization in which the summary statistics relating to single-nucleotide polymorphisms from 5,839 genome-wide association

studies of exposures were used to assess causal relationships with PD. We selected the highest-quality exposure genome-wide association studies for this report ($n = 401$). For the disease outcome, summary statistics from the largest published PD genome-wide association studies were used. For each exposure, the causal effect on PD was assessed using the inverse variance weighted method, followed by a range of sensitivity analyses. We used a false discovery rate of 5% from the inverse variance weighted analysis to prioritize exposures of interest.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

***Correspondence to:** Dr. Alastair Noyce, Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, United Kingdom; E-mail: a.noyce@qmul.ac.uk

AJ Noyce, S Bandres-Ciga, and J Kim made an equal contribution.

Funding agencies: This research was supported, in part, by the Intramural Research Program of the National Institutes of Health (National Institute on Aging, National Institute of Neurological Disorders and Stroke; project numbers 1ZIA-NS003154, Z01-AG000949-02, and Z01-ES101986. The QMUL Preventive Neurology Unit is funded by the Barts Charity: grant reference number MGU0364. George Davey Smith and Debbie Lawlor work in the Medical Research Council Integrative Epidemiology Unit at the University of Bristol, which is supported by the Medical Research Council (MC_UU_00011/1). University College

London Hospitals and University College London receive support from the Department of Health's National Institute for Health Research (NIHR) Biomedical Research Centres (BRC). Debbie Lawlor and Nicholas Wood are NIHR senior investigators.

Relevant conflicts of interest/financial disclosures: Mike A. Nalls' participation is supported by a consulting contract between Data Tecnica International and the National Institute on Aging, NIH (Bethesda, MD). As a possible conflict of interest Dr. Nalls also consults for SK Therapeutics Inc, Lysosomal Therapeutics Inc, the Michael J. Fox Foundation, and Vivid Genomics among others.

Full financial disclosures and author roles may be found in the online version of this article.

Received: 11 April 2019; **Revised:** 5 August 2019; **Accepted:** 4 September 2019

Published online 28 October 2019 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.27873

Results: We observed evidence for causal associations between 12 exposures and risk of PD. Of these, nine were effects related to increasing adiposity and decreasing risk of PD. The remaining top three exposures that affected PD risk were tea drinking, time spent watching television, and forced vital capacity, but these may have been biased and were less convincing. Other exposures at nominal statistical significance included inverse effects of smoking and alcohol.

Conclusions: We present a new platform which offers Mendelian randomization analyses for a total of 5,839

genome-wide association studies versus the largest PD genome-wide association studies available (<https://pdgenetics.shinyapps.io/MRportal/>). Alongside, we report further evidence to support a causal role for adiposity on lowering the risk of PD. © 2019 The Authors. *Movement Disorders* published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Key Words: Mendelian randomization; Parkinson's disease; public resource; risk factor

Although monogenic forms of Parkinson's disease (PD) are responsible for approximately 5% of cases, the vast majority of disease is considered to be sporadic and attributable to a range of genetic and nongenetic risk factors.¹ Total heritability estimates for PD are 22% to 27%, with approximately one-third of this explained by genome-wide association studies (GWAS) and a substantial proportion of genetic risk still to be discovered.²⁻⁵ The remainder of PD risk comes from environmental factors,^{4,5} aging,^{6,7} and stochastic events.⁸

Mendelian randomization (MR) is an epidemiological method that can be used to provide support for causality between a modifiable exposure/risk factor/phenotypic trait (henceforth collectively termed *exposure*) and a disease outcome.⁹ Put simply, genetic variants (usually single-nucleotide polymorphisms [SNPs]) that explain variation in an exposure can be used as proxies to determine how a change in that exposure might influence a disease outcome. A ratio of the genetically estimated change in the exposure and the genetically estimated change in the outcome using the same individual SNP is calculated and then the ratios are pooled across all SNPs that are independently associated with the exposure of interest. The pooled ratio is an estimate of change in the outcome for a given change in the exposure, as long as certain instrumental variable assumptions are upheld (see Supporting Information).

A common approach to MR involves the use of summary statistics from published GWASes of exposures and the summary statistics of a GWAS of an outcome; an approach known as two-sample MR. Recently, the summary statistics from GWAS for a large range of exposures have been curated in *MR Base* (<http://www.mrbase.org>), which enables targeted (hypothesis-driven) exploration of causal associations or hypothesis-generating approaches to MR.¹⁰ We have undertaken two-sample MR for a wide range of exposures and PD. The principal goal was to provide a new resource for the research community to add causal insights to associations arising from traditional epidemiological approaches and to support the pursuit of new interventions to reduce the risk of PD.

Materials and Methods

Exposure Data

MR Base is an online resource which, at the time of the analysis, contained summary results from 7,956 GWASes across multiple exposures, encompassing a wide range of physiological characteristics and disease phenotypes. *MR Base* was accessed on January 14, 2019. Each exposure was tested separately to determine whether it altered risk of PD. All analyses were performed using the R package, *TwoSampleMR* (version 3.2.2; <https://github.com/MRCIEU/TwoSampleMR>). The instrumental variables used for each binary exposure consisted of the per-allele log-odds ratio (or the beta estimate for continuous exposures) and standard errors for all independent GWAS significant SNPs.

We used the following stringent criteria for any exposure GWAS to be included in our analysis: (1) the GWAS had to report SNPs with P values $< 5.0 \times 10^{-8}$ for their association with a given exposure; (2) these SNPs or their proxies (linkage disequilibrium R^2 value ≥ 0.8) had to be present in both the exposure and outcome (PD) data sets; and (3) these SNPs were independent signals that were generated through a process called "clumping." In order to "clump," index SNPs were identified by ranking exposure associations from the smallest to largest P value (but still with a cut-off value of $P = 5 \times 10^{-8}$). Clumped SNPs were those in linkage disequilibrium (LD) with index SNPs (R^2 threshold of 0.001) or within 10,000 kb physical distance. Hence, each index SNP represented a number of clumped SNPs that were all associated with or near to the index SNP, and the index SNPs were all independent of one another (according to the stringent parameters defined here). A total of 5,839 exposure GWASes surpassed these criteria and were tested against the outcome. Then, we further expanded our filtering approach as follows: (4) in order to use MR sensitivity analyses designed to identify pleiotropy and its effects, each GWAS had to include a minimum of 10 associated SNPs; (5) the number of cases was > 250 for GWASes of a binary exposure or > 250 individuals for GWASes of a continuous exposure; and (6) both the exposure

and the outcome data were drawn from European populations. A total of 401 exposures met our filtering criteria (7% of 5,839), consisting of 175 published GWASes and 226 unpublished GWASes from the UK Biobank (UKB; www.ukbiobank.ac.uk). For UKB GWASes, some of the exposures are reported in an ordinal fashion, but treated as continuous when calculating betas for the effect allele at each SNP. This means that some of the effect estimates that arise are difficult to interpret quantitatively, both in the GWAS and in the subsequent MR analysis.

Outcome Data

Summary statistics from the largest, published PD GWAS meta-analysis involving 26,035 PD cases and 403,190 controls of European ancestry were used as the outcome data for the primary analysis. Recruitment and genotyping quality-control procedures were described in the original report.¹¹

A newer PD GWAS included a total of 37,688 cases, 1,417,791 controls, and 18,618 “proxy cases” from the UKB (individuals that reported having a parent with PD).² However, there was substantial overlap in control subjects between each of the UKB exposures and the Nalls and colleagues 2019 meta-analysis, which can, in turn, lead to bias in causal effect estimates. For this reason, we repeated the analyses using only 5,851 clinically diagnosed PD cases and 5,866 matched controls as the outcome, after excluding UKB samples and self-reported PD cases and controls. Finally, we used an earlier PD GWAS as the outcome that included 13,708 cases and 95,282 controls.¹²

MR Analyses

Harmonization was undertaken to rule out strand mismatches and to ensure alignment of SNP effect sizes. Wald ratios were calculated for each clumped SNP in the exposure GWAS by dividing the per-allele log-odds ratio (or beta) of that variant in the PD GWAS data by the log-odds ratio (or beta) of the same variant in the exposure data.

First, the inverse-variance weighted (IVW) method was implemented to examine the relationship between the individual exposures and PD. In this method, the Wald ratio for each SNP was weighted according to its inverse variance and the effect estimates were meta-analyzed using random effects. This approach is equivalent to plotting SNP-exposure/SNP-outcome associations on scatter plot and fitting a regression line (IVW regression), which is constrained to pass through the origin. The slope of the linear regression represents the pooled-effect estimate of the individual SNP Wald ratios.¹³ For the purpose of demonstrating the use of this new platform, we used a false discovery rate (FDR)-adjusted *P* value of <0.05 to define exposures

of interest as showing potential evidence of a causal effect. The IVW estimate is valid when the three core assumptions that underpin MR are upheld (see Supporting Information). However, simulation studies show that up to 90% of MR analysis may be affected by pleiotropy, which, in turn, may bias the IVW estimate.¹⁴ Effects of pleiotropy for each analysis were studied by first looking for evidence of heterogeneity in the SNP Wald ratios and then undertaking a range of sensitivity analyses, each with different underlying assumptions.

Heterogeneity in the IVW estimates was tested using Cochran’s *Q* test, quantified using the I^2 statistic, and displayed in forest plots. Heterogeneity in the IVW estimate may indicate that alternative pathways exist from some of the SNPs to the outcome (known as horizontal pleiotropy), which can violate the third MR assumption,¹⁵ but as long as overall heterogeneity is balanced it does not necessarily bias the pooled IVW estimate.¹⁶ After calculation of the IVW estimates, three sensitivity analyses were applied to evaluate the core assumptions of MR. These rely on instruments containing multiple SNPs (in this case a minimum of 10 SNPs per exposure).¹⁷

MR-Egger was used, in which the regression line fitted to the data is not constrained to pass through the origin and a nonzero intercept indicates whether there is a net horizontal pleiotropic effect which may bias the IVW estimate.¹⁸ The weighted median (WM) MR method gives consistent effect estimates under the assumption that no more than 50% of the weight of the MR effect estimate comes from invalid (e.g., pleiotropic) SNPs, where weight is determined by the strength of their association with the exposure.¹⁹ Finally, IVW radial analysis was performed as a complementary method to account for SNPs acting as heterogeneous outliers and to determine the effect of resulting bias on the IVW estimate.¹⁶

Exploring Directionality, Single SNP Effects, and Reverse Causality


For effect estimate directionality, odds ratios were scaled on a standard deviation increase in genetic risk for the exposure from that population mean. We evaluated the possibility that the overall estimate was driven by a single SNP using leave-one-out (LOO) analyses for each of the exposures associated with PD. Finally, we tested for reverse causation by using SNPs tagging the independent loci described in the latest PD GWAS as exposure instrumental variables and exposure GWASes as the outcomes. Note that this analysis measures the causal effect of genetic liability toward PD on each of the exposures included in the main analysis, which is independent of PD actually occurring (in a case-control setting such as this).

Results

The PD MR Research Portal is hosted at <https://pdgenetics.shinyapps.io/MRportal/>. Here, we explore some of the top results to assist users in understanding

how to interpret these data (see Fig. 1 for flowchart of analysis).

Of the 401 exposures that survived the filtering process, we found 12 exposures with potentially causal effects on PD (i.e., IWV FDR-adjusted P values <0.05 ;



MR Base GWASes are available at <http://www.mrbase.org/>; GWAS, Genome-Wide Association study; * denotes only clinically diagnosed PD cases

FIG. 1. Flowchart of analysis. The PD MR Research Portal is an interactive tool where the user can explore causal associations across multiple exposures. (1) The inclusion criteria used include (i) GWASes with associated SNPs with P values $<5.0 \times 10^{-8}$; (ii) SNPs present in both the exposure and outcomes (Chang and colleagues 2017 as the primary analysis, Nalls and colleagues 2019 with only clinically diagnosed cases, and Nalls and colleagues 2014) data sets or when not present their LD proxies (R^2 value: ≥ 0.8); and (iii) independent SNPs ($R^2 < 0.001$ with any other associated SNP within 10 Mb), considered as the most stringent clumping threshold used when performing MR analyses. A total of 5,839 GWASes surpassed this criteria and were tested against the three outcomes. (2) Then, we further expanded our filtering approach as follows: (iv) each GWAS had to include a minimum of 10 associated SNPs in order to use MR sensitivity analyses designed to identify pleiotropy; (v) the number of cases had to be >250 for each GWAS of a given binary exposure or > 250 individuals for each GWAS of a given continuous exposure; and (vi) the exposure and the outcome data sets were drawn from European populations. A total of 401 exposures surpassed our filtering approach consisting of 175 published GWASes and 226 unpublished GWASes from the UKB (www.ukbiobank.ac.uk). [Color figure can be viewed at wileyonlinelibrary.com]

see Table 1 and Supporting Information Fig. S1 for forest plots displaying individual SNP-level estimates and pooled estimates). Of these exposures, nine were measures of adiposity that implied an inverse causal effect of increase adiposity and a lowering of PD risk. Three additional exposures met the FDR-adjusted *P*-value threshold for a possible causal effect: time spent watching television (inverse), tea drinking (positive), and forced vital capacity (FVC; positive). In each case, to explore the possibility that results were biased because of the violation of core MR assumptions, we looked for heterogeneity in the individual Wald ratios and performed the three additional MR sensitivity analyses (see Table 2 for heterogeneity analyses and Table 1 for sensitivity analyses).

The eight direct adiposity GWASes all contained >200 SNPs and were highly correlated with one another. The strongest causal effects were observed for arm fat percentage, which was measured using tissue impedance (<https://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=23119>). A unit increase in arm fat percentage (right and left) yielded a pooled odds ratio (OR) of 0.65 (95% confidence interval [CI]: 0.54–0.79; *FDR adjusted P* = 0.005) and a pooled OR of 0.66 (95% CI: 0.54–0.79; *FDR adjusted P* = 0.01), respectively. Although the individual Wald ratios showed significant heterogeneity (arm fat percentage [right] *Q* = 314.8; *P* = 7.01 × 10⁻⁶; arm fat percentage [left] *Q* = 399.38; *P* = 3.93 × 10⁻¹¹), the sensitivity analyses did not suggest significant bias in the causal effect estimate from the IVW analysis (see Table 2 for heterogeneity analyses and Table 1 for sensitivity analyses). In general, all effect estimates for the adiposity exposures supported a protective effect of increased adiposity on risk of PD (ORs ranged between 0.62 and 0.77; see Table 1).

Another adiposity exposure called “impedance of right leg” surpassed the IVW FDR-adjusted *P*-value threshold. As described above, impedance is the method by which percentage fat is calculated, with higher impedance indicative of higher fat percentage (<https://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=23107>). Given the results for adiposity, we expected that a unit change in impedance would result in a lowering of PD risk. In contrast to the results for adiposity, the impedance exposure gave rise to an IVW OR of 1.25 (95% CI: 1.10–1.42; *FDR adjusted P* = 0.032). There was significant heterogeneity in the individual Wald ratios (*Q* = 428.4; *P* = 7.25 × 10⁻⁷), but the sensitivity analyses did not suggest bias in the IVW effect estimate (see Table 2 for heterogeneity analyses and Table 1 for sensitivity analyses). We sought to explain why the direction of effect for impedance was different to that for percentage fat, when it was expected that it should be the same. Genetic correlations between impedance and percentage fat were run (see Supporting Information Table S1), and in all cases

TABLE 1. Mendelian randomization analyses of exposures with IVW FDR < 0.05 vs Chang et al., 2017

Exposure	no. of SNPs	IVW			MR Egger			Weighted Median			Radial IVW			
		beta	se	p-value	FDR	beta	se	p-value	beta	se	p-value	beta	se	p-value
Arm fat percentage (right) id:UKB-a:282	214	-0.431	0.098	1.10E-05	0.005	-0.657	0.324	0.044	-0.372	0.143	0.009	-0.454	0.079	3.35E-08
Arm fat percentage (left) id:UKB-a:286	233	-0.417	0.103	4.94E-05	0.010	-0.790	0.333	0.018	-0.201	0.137	0.143	-0.434	0.077	5.41E-08
Arm fat mass (right) id:UKB-a:283	248	-0.276	0.072	1.32E-04	0.011	-0.305	0.218	0.164	-0.299	0.100	0.003	-0.271	0.056	2.44E-06
Leg fat percentage (right) id:UKB-a:274	228	-0.482	0.126	1.33E-04	0.011	-0.944	0.479	0.050	-0.436	0.158	0.006	-0.465	0.096	2.54E-06
Whole body fat mass id:UKB-a:265	258	-0.269	0.070	1.35E-04	0.011	-0.362	0.220	0.102	-0.241	0.102	0.018	-0.281	0.056	7.95E-07
Arm fat mass (left) id:UKB-a:287	248	-0.279	0.074	1.58E-04	0.011	-0.492	0.222	0.027	-0.307	0.105	0.004	-0.288	0.056	6.07E-07
Trunk fat mass id:UKB-a:291	257	-0.259	0.070	2.10E-04	0.012	-0.438	0.227	0.055	-0.256	0.094	0.007	-0.255	0.054	4.37E-06
Time spent watching television (TV) id:UKB-b:5192	104	-0.775	0.211	2.40E-04	0.013	-0.166	1.016	0.870	-0.586	0.234	0.012	-0.772	0.156	2.81E-06
Trunk fat percentage id:UKB-a:290	216	-0.307	0.085	3.20E-04	0.015	-0.554	0.307	0.073	-0.217	0.111	0.050	-0.325	0.066	1.49E-06
Forced vital capacity (FVC) Best measure id:UKB-a:232	179	0.441	0.128	5.80E-04	0.024	0.940	0.381	0.015	0.241	0.123	0.050	0.455	0.075	6.27E-09
Tea intake id:UKB-b:6066	35	0.554	0.163	6.58E-04	0.025	0.710	0.334	0.041	0.543	0.223	0.015	0.570	0.143	2.97E-04
Impedance of leg (right) id:UKB-a:270	294	0.220	0.066	9.17E-04	0.032	0.212	0.189	0.263	0.315	0.091	0.001	0.233	0.054	2.14E-05

id, specific code attributed to each trait by MR Base; se, standard error; MR, Mendelian randomization; IVW, Inverse Variance Weighted; FDR, false discovery rate adjusted p value.

TABLE 2. Heterogeneity, horizontal pleiotropy and directionality analyses for exposures with FDR < 0.05 vs Chang et al. 2017

Exposure	Horizontal pleiotropy				Heterogeneity				Directionality	
	Egger intercept	se	p-value	MR Egger Q	MR Egger Q df	MR Egger p-value	IWW Q	IWW Q df		IWW p-value
Arm fat percentage (right) id:UKB-a:282	3.684E-03	0.005	0.466	314.024	212	6.521E-06	314.816	213	7.006E-06	-
Arm fat percentage (left) id:UKB-a:286	5.959E-03	0.005	0.239	399.388	231	3.926E-11	401.794	232	3.090E-11	-
Arm fat mass (right) id:UKB-a:283	6.229E-04	0.004	0.887	394.669	246	5.351E-09	394.701	247	6.786E-09	-
Leg fat percentage (right) id:UKB-a:274	5.925E-03	0.006	0.319	374.029	226	2.108E-09	375.682	227	1.951E-09	-
Whole body fat mass id:UKB-a:265	1.975E-03	0.004	0.656	399.929	256	2.122E-08	400.239	257	2.523E-08	-
Arm fat mass (left) id:UKB-a:287	4.548E-03	0.004	0.309	408.501	246	3.374E-10	410.229	247	3.076E-10	-
Trunk fat mass id:UKB-a:291	3.900E-03	0.005	0.408	412.287	256	2.001E-09	411.179	255	1.942E-09	-
Time spent watching television (TV) id:UKB-b:5192	-7.167E-03	0.012	0.542	186.037	102	7.452E-07	186.721	103	8.687E-07	-
Trunk fat percentage id:UKB-a:290	4.814E-03	0.006	0.405	352.411	214	7.667E-09	353.559	215	7.863E-09	-
Forced vital capacity (FVC) Best measure id:UKB-a:232	-9.804E-03	0.007	0.166	497.966	177	2.655E-32	503.407	178	7.621E-33	+
Tea intake id:UKB-b:6066	-3.608E-03	0.007	0.596	40.971	33	1.605E-01	41.327	34	1.811E-01	+
Impedance of leg (right) id:UKB-a:270	1.645E-04	0.004	0.965	427.081	292	4.081E-07	427.084	293	4.972E-07	+

id, specific code attributed to each trait by MR Base; se, standard error; IWW, Inverse variance weighted; MR, Mendelian randomization; Q, Cochran's Q test estimate; df, Cochran's Q test degrees of freedom.

the genetic association between the two exposures was negative.

The “tea drinking” exposure was captured by an instrument containing 35 SNPs. The IVW OR was 1.74 (95% CI: 1.26–2.39; *FDR adjusted P* = 0.025), and there was no significant heterogeneity in the individual Wald ratios (*Q* = 41.3; *P* = 0.181). The sensitivity analyses did not imply bias in the IVW estimate. Of note, coffee intake was not causally associated with increased risk of PD (OR, 1.37; *P* = 0.197), but similar to the tea drinking exposure, the direction of effect was also not consistent with the recognized negative observational effect.

“Time spent watching television” was inversely linked to PD risk in the IVW analysis (OR, 0.46; *FDR adjusted P* = 0.013), suggesting that more time spent watching television caused a lower risk of PD. However, the MR Egger sensitivity analysis gave a very different pooled effect estimate (OR, 0.85; *P* = 0.870), suggesting that the IVW result may have been biased by directional pleiotropy. The intercept term can be used to test for net directional pleiotropy (here it was -0.007; *P* = 0.542), but this test is generally underpowered. The difference in the slope from the IVW analysis and the MR Egger analysis is shown graphically in Supporting Information Figure S2, and suggests that, in the presence of directional pleiotropy, the IVW effect for time spent watching television may be overestimated. From the other scatter and forest plots, it is clear that for the adiposity exposures, that the slope (or magnitude of effect) the MR Egger regression is greater than the IVW slope (effect), which suggests that in the presence of directional pleiotropy, the IVW may be underestimated.

“Forced vital capacity” showed a positive causal effect on PD risk that was similarly observed in the sensitivity analyses (see Table 1). However, the effects appeared to be largely driven by two SNPs known to be pleiotropic for PD (see below).

The LOO analysis showed that none of the results described for the 12 exposures were explained by a single SNP in each of the instruments (Supporting Information Table S2). The most precisely estimated Wald ratio for most of the adiposity exposures (seven of eight) came from a single SNP in the *FTO* gene (rs11642015), but dropping this SNP from the analyses did not affect the overall results. Similarly, the most precisely estimated Wald ratio in the impedance instrument was for a different SNP in the *FTO* gene (rs62048402), but again dropping this SNP did not affect the overall results. Importantly, and in support of the observations relating to negative genetic correlation between percentage fat and impedance described above, the direction of the Wald ratio for the *FTO* SNP in adiposity exposures was negative and for impedance was positive.

For tea drinking, the two Wald ratios with the greatest influence on the pooled effect estimates came from SNPs rs4410790 and rs2472297 (located in the *AHR* and *CYP1A2* gene loci respectively), which are known to be strongly associated with caffeine consumption.²⁰ Leaving either SNP out from the analysis did not change the overall result, but the pooled effect estimate weakened when rs4410790 (*AHR*) was removed (the OR 1.74 changed to 1.61). In the forced vital capacity analysis, SNPs rs1991556 and rs13146142 were most precisely estimated and appeared to influence the magnitude of the causal effect. Closer examination revealed that rs1991556 is in the *MAPT* locus and rs13146142 is in the *LCORL* locus, and both are known to be associated with PD, likely biasing the causal effect of FVC on PD.^{2,12}

The reverse causation analyses revealed no clear evidence that a liability toward PD was causally linked with any of the 12 exposures, but this analysis was restricted to only 18 of the 43 PD GWAS significant hits and may have been underpowered (Supporting Information Table S3).

Of interest, the next seven exposures with the strongest associations in the IVW analysis, but not surpassing the FDR-adjusted *P*-value threshold, were four adiposity traits (all showing a negative causal effect), current tobacco smoking (negative causal effect), increased alcohol intake (negative causal effect), and increased education (having a college or university degree; positive causal effect). The FDR-adjusted *P* values for each of these were < 0.1 and unadjusted *P* values were all < 0.004.

Finally, we used clinically diagnosed cases (and controls) from the 2019 PD GWAS dataset as the outcome (Supporting Information Table S4). Given the smaller sample size, none of the MR analyses surpassed an FDR-adjusted *P* value, but the top hit was a marker of adiposity (hip circumference). When an even earlier iteration of the PD GWAS was used (~13.5k cases and ~95k controls),¹² there were 11 exposures that surpassed the FDR-adjusted *P*-value threshold and all 11 were related to adiposity (Supporting Information Table S5).

Discussion

We envisage the PD MR Research Portal being a valuable and evolving resource for the global research community, which will be updated as new data emerge. It should be used to provide evidence to support, and, over time, evidence against, causality when undertaking observational studies or pursuing interventions aimed at reducing the risk of PD. Clearly, there are too many associations presented in the portal to explore each one in detail. So, for the purpose of demonstrating the tool,

we undertook a data-driven approach to identify those exposures with the strongest causal signals.

We have previously reported an inverse causal association between body mass index (BMI) and risk of PD—a genetically estimated 5 kg/m² higher BMI was associated with a reduced risk of PD (IVW OR = 0.82).²¹ Here, we found further evidence to support an inverse relationship between increased adiposity and PD, given that eight of the top 12 exposures were measures of adiposity. These exposures were objectively and quantitatively ascertained, and each GWAS identified >200 SNPs that were associated with increased adiposity. The results of the IVW analyses and all sensitivity analyses were broadly consistent. Impedance (the ninth adiposity exposure in the analysis) gave rise to a causal effect opposite to that of increasing the other adiposity exposures, which was initially unexpected. The difference in the direction of effect may be because the equation that links percentage fat and impedance requires adjustment for height and weight, which would not have been done routinely in the impedance GWAS.²²

Of note, although BMI was not one of the top 12 exposures, the causal effect of BMI on PD was also negative in this analysis (OR, 0.81; *P* = 0.037), using the same BMI instrument that we have previously published on.^{21,23} In that earlier analysis, we included simulations that indicated that the protective effect was unlikely to be explained by survival bias (i.e., people with higher BMI dying of other diseases before they would usually be diagnosed with PD). The relationship between BMI and adiposity with risk of PD clearly warrants further study, especially given uncertainty in the role of BMI arising from traditional observational studies.^{21,24}

We found no evidence to support a protective effect of coffee and tea drinking, and instead unexpectedly found some evidence that tea drinking may increase the risk of PD. Observational study associations between caffeine-containing drinks (both coffee and tea) have consistently suggested a negative association with PD, and caffeine has been explored as a potentially therapeutic option for PD.^{4,25,26} Our results should not be considered in isolation given a large body of observational evidence, which has been amassed from well-conducted prospective studies using detailed dietary questionnaires and long durations of follow-up. Clearly, using a genetic instrument to capture a behavior reported by a question in the UKB survey may be flawed compared to the traditional approaches outlined above. However, the current findings perhaps provide some indirect support for the notion that negative associations between caffeine consumption and PD may be driven by reverse causation rather than a true protective effect, and this warrants further study.

In contrast to tea drinking, there was some evidence to support a true protective effect of smoking, which

fell below the threshold to be discussed as a top result. The remaining two exposures (time spent watching television and forced vital capacity) that appeared to be causally linked to PD should be regarded with caution. Television watching failed in one of the sensitivity analyses and the effect of forced vital capacity appeared to be driven, in part, by two recognized PD SNPs, rendering these two results potentially invalid.

Alongside a standard method used to pool ratio estimates from individual SNPs (the IVW method), we also demonstrated the use of three sensitivity analyses that provide more valid estimates when core instrumental variable assumptions have been violated (namely the MR-Egger, WM, and radial methods).^{16,19} These methods will allow researchers to further appraise the validity of the instruments presented and whether IVW estimates may be biased. In the current version of the portal, we have provided the opportunity of undertaking analyses with three different PD outcome data sets. There was little qualitative difference in the “top MR hits” across the three iterations of the PD outcome data, particularly when comparing the larger data sets. The portal also contains a huge number of exposures that have been curated by *MR Base*. However, as highlighted in this report and in a warning message in the portal, we advise caution with the interpretation of results for exposures that do not surpass considered filtering criteria (for our criteria, this was 5,438 of 5,839 or 93% of exposures). These included GWASes for which the case numbers were small and the number of variants in the exposure instruments was too few to permit the use of the sensitivity analyses. ■

Limitations

The general limitations of MR have been covered extensively elsewhere,⁹ but include issues of statistical power (large sample sizes are required for these analyses), selection bias (which may arise through population stratification and is mitigated here by using only European ancestry GWASes), survival bias (particularly with age-related outcomes such as PD, which we have discussed above), overlapping control groups (which may bias effect estimates, but have been avoided here), and violation in underlying MR assumptions (which are tested by a range of sensitivity analyses). In most instances, the variation in a given exposure that is explained by genome-wide significant GWAS signals is small (i.e., 0.5–8%), meaning that sample sizes often need to be extremely large to detect causal effects using this design. The resulting *P* values that arise from MR hypothesis tests are often not small and, in the various sensitivity analyses, often border on or exceed nominal statistical significance. Given the approach, traditional methods of adjusting for multiple comparisons (i.e., Bonferroni or FDR correction) render many

potentially causal associations obsolete and limit the conclusions that one can draw. In general, we recommend using this tool to confirm or add to evidence to associations identified in observational studies or toward a particular intervention. It is generally recommended that emphasis should be placed on the confidence intervals and consistency of point estimates across the IVW estimate and the sensitivity analyses, rather than just the *P* values *per se*. In addition, we recommend the calculation of F-statistics for determining instrument strength and post-hoc power calculations, particularly in the instance of null results.^{2,27} This is particularly important when making claims of *no evidence* to support a causal association (such as in some of the reverse causation analyses presented in this article). These additions, and others, are planned for future versions of the portal.

For all analyses presented here, the outcome is “risk of PD” because the outcome data come from a GWAS of PD cases versus controls. In order to make causal inferences about the effect of various exposures on disease progression, one would need to have an outcome GWAS of PD progression. As mentioned in the Materials and Methods, an important source of bias in MR studies can occur when there is overlap in the control groups in the exposure and outcome data. For this reason, all UKB data were removed from the outcome PD GWAS summary statistics.

In summary, we present a new portal for use by the research community that will help assess causality where observational associations exist and prioritize (or deprioritize) interventions aimed at reducing risk of PD.

Acknowledgments: We thank the research participants for their contribution to the GWAS used here. We thank Zhihong Zhu (Queensland) who contributed to the discussion on MR methods. We thank the following members of the 23andMe Research Team: Michelle Agee, Babak Alipanahi, Adam Auton, Robert K. Bell, Katarzyna Bryc, Sarah L. Elson, Pierre Fontanillas, Nicholas A. Furlotte, Barry Hicks, Karen E. Huber, Ethan M. Jewett, Yunxuan Jiang, Aaron Kleinman, Keng-Han Lin, Nadia K. Litterman, Jennifer C. McCreight, Matthew H. McIntyre, Kimberly F. McManus, Joanna L. Mountain, Elizabeth S. Noblin, Carrie A.M. Northover, Steven J. Pitts, G. David Poznik, J. Fah Sathirapongsasuti, Janie F. Shelton, Suyash Shringarpure, Chao Tian, Joyce Y. Tung, Vladimir Vacic, Xin Wang, and Catherine H. Wilson.

References

1. Billingsley KJ, Bandres-Ciga S, Saez-Atienzar S, Singleton AB. Genetic risk factors in Parkinson's disease. *Cell Tissue Res* 2018; 373:9–20.
2. Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome wide association studies. *Lancet Neurology* 2019 [in press].
3. Wray NR, Yang J, Goddard ME, Visscher PM. The genetic interpretation of area under the ROC curve in genomic profiling. *PLoS Genet* 2010;6:e1000864.
4. Noyce AJ, Bestwick JP, Silveira-Moriyama L, et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. *Ann Neurol* 2012;72:893–901.

5. Berg D, Postuma RB, Adler CH, et al. MDS research criteria for prodromal Parkinson's disease. *Mov Disord* 2015;30:1600–1611.
6. Collier TJ, Kanaan NM, Kordower JH. Aging and Parkinson's disease: different sides of the same coin? *Mov Disord* 2017;32:983–990.
7. Reeve A, Simcox E, Turnbull D. Ageing and Parkinson's disease: why is advancing age the biggest risk factor? *Ageing Res Rev* 2014;14:19–30.
8. Smith GD. Epidemiology, epigenetics and the “Gloomy Prospect”: embracing randomness in population health research and practice. *Int J Epidemiol* 2011;40:537–562.
9. Lawlor DA, Harbord RM, Sterne JAC, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. *Stat Med* 2008;27:1133–1163.
10. Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the human phenome. *Elife* 2018;7:e34408.
11. Chang D, Nalls MA, Hallgrímsson IB, et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci. *Nat Genet* 2017;49:1511–1516.
12. Nalls MA, Pankratz N, Lill CM, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. *Nat Genet* 2014;46:989–993.
13. Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for Mendelian randomization. *Stat Methods Med Res* 2017;26:2333–2355.
14. Hemani G, Bowden J, Haycock PC, et al. Automating Mendelian randomization through machine learning to construct a putative causal map of the human phenome. *bioRxiv* 2017 Aug 23. doi: <https://doi.org/10.1101/173682>. [Epub ahead of print]
15. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. *Hum Mol Genet* 2014;23:R89–R98.
16. Bowden J, Spiller W, Del Greco M F, et al. Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the Radial plot and Radial regression. *Int J Epidemiol* 2018;47:1264–1278.
17. Hemani G, Bowden J, Davey Smith G. Evaluating the potential role of pleiotropy in Mendelian randomization studies. *Hum Mol Genet* 2018;27:R195–R208.
18. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol* 2015;44:512–525.
19. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. *Genet Epidemiol* 2016;40:304–314.
20. Coffee and Caffeine Genetics Consortium, Cornelis MC, Byrne EM, et al. Genome-wide meta-analysis identifies six novel loci associated with habitual coffee consumption. *Mol Psychiatry* 2015;20:647–656.
21. Noyce AJ, Kia DA, Hemani G, et al. Estimating the causal influence of body mass index on risk of Parkinson disease: a Mendelian randomisation study. *PLoS Med* 2017;14: e1002314.
22. Jebb SA, Cole TJ, Doman D, Murgatroyd PR, Prentice AM. Evaluation of the novel Tanita body-fat analyser to measure body composition by comparison with a four-compartment model. *Br J Nutr* 2000;83:115–122.
23. Locke AE, Kahali B, Berndt SI, et al. Genetic studies of body mass index yield new insights for obesity biology. *Nature* 2015;518:197–206.
24. Wang YL, Wang YT, Li JF, Zhang YZ, Yin HL, Han B. Body mass index and risk of Parkinson's disease: a dose-response meta-analysis of prospective studies. *PLoS One* 2015;10: e0131778.
25. Qi H, Li S. Dose-response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson's disease. *Geriatr Gerontol Int* 2014;14:430–439.
26. Postuma RB, Anang J, Pelletier A, et al. Caffeine as symptomatic treatment for Parkinson disease (Café-PD). *Neurology* 2017;89:1795–1803.
27. Brion MJA, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. *Int J Epidemiol* 2013;42:1497–1501.

Supporting Data

Additional Supporting Information may be found in the online version of this article at the publisher's web-site.